SITE004-0265

SITE004 (DEU) › SITE004-0265

SITE004-0265

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE004 (DEU) · Dr. Tanaka
consented 2026-07-20

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-02-15 (study day 26); relationship: NOT RELATED

mild assessed

Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-01-26 (study day 6); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.